Synapsin I Protein

📖 Wiki Page

protein1306 wordssynced 2026-04-02

Synapsin I Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Synapsin I Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SYN1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Synapsin I</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=SYN1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">148 edges</a></td>
</tr>
</table>

Overview

...

Synapsin I Protein

Overview

Synapsin I (also known as Synapsin-1 or SYN1) is a neuronal phosphoprotein that plays a crucial role in regulating synaptic transmission and synaptic vesicle dynamics at the presynaptic terminal. As one of the most abundant synaptic proteins, Synapsin I serves as a molecular linker between synaptic vesicles and the actin cytoskeleton, facilitating vesicle clustering, mobilization, and release. This protein is essential for maintaining synaptic plasticity and long-term potentiation, processes fundamental to learning, memory, and adaptive neuronal responses[^1].

Molecular Structure and Composition

Synapsin I is a ~80 kDa protein composed of several functionally distinct domains that enable its diverse roles in synaptic regulation:[^2]

N-terminal Domain (Domains A and B): Contains the primary sites for phosphorylation by calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA), crucial for regulating synaptic vesicle release and activity-dependent plasticity[^3]
C-terminal Domain: Rich in proline residues, facilitating interactions with actin filaments and other cytoskeletal elements through its ability to bind F-actin
Linker Region: Provides structural flexibility and mediates protein-protein interactions essential for vesicle clustering
Phosphorylation Sites: Contains multiple consensus sequences for phosphorylation by various kinases, enabling rapid modulation of function in response to neuronal activity[^4]

The protein exists as multiple isoforms (SynI-a and SynI-b) generated through alternative splicing, with distinct tissue distributions and functional properties.

Key Mechanisms and Functions

Synaptic Vesicle Clustering and Mobilization: Synapsin I tethers synaptic vesicles to the actin cytoskeleton through its C-terminal domain, maintaining the reserve pool of vesicles in close proximity to the release machinery. Phosphorylation of Synapsin I by CaMKII and PKA causes conformational changes that weaken vesicle-actin interactions, facilitating mobilization of reserve pool vesicles to the readily releasable pool (RRP) in response to neuronal stimulation (PMID:8144738)[^5].
Regulation of Neurotransmitter Release: By controlling vesicle availability and positioning, Synapsin I modulates the amplitude and frequency of synaptic transmission. Mice lacking Synapsin I exhibit reduced synaptic strength and impaired high-frequency synaptic transmission, demonstrating its critical role in sustaining neurotransmitter release during prolonged activity (PMID:10433185)[^6].
Activity-Dependent Phosphorylation: Synapsin I undergoes rapid phosphorylation at multiple sites in response to calcium influx and neuronal activity. Phosphorylation by CaMKII at sites 1 and 2 is particularly important for activity-dependent synaptic potentiation, while PKA-mediated phosphorylation at site 3 regulates presynaptic inhibition through G-protein coupled receptors (PMID:8534009)[^7].
Cytoskeletal Organization and Actin Dynamics: The interaction between Synapsin I and F-actin is critical for maintaining synaptic structure and facilitating rapid changes in vesicle positioning. This interaction is dynamically regulated by phosphorylation and represents a key mechanism linking neuronal activity to morphological changes at the synapse (PMID:11146036)[^8].
Synaptic Plasticity and Learning: Long-term potentiation (LTP) and long-term depression (LTD) both involve dynamic phosphorylation and dephosphorylation of Synapsin I. These modifications regulate the stabilization of synaptic strength changes and are essential for memory consolidation, as demonstrated by impaired learning in Synapsin I knockout mice (PMID:10433184).

Relevance to Neurodegeneration and Disease

Neurodegenerative Pathology

Synapsin I dysfunction has been implicated in multiple neurodegenerative diseases through both direct and indirect mechanisms. In Alzheimer's disease, progressive loss of Synapsin I immunoreactivity correlates strongly with cognitive decline and synaptic dysfunction, reflecting the early synaptic pathology that characterizes the disease (PMID:16085084). This loss appears to precede significant neuronal death, suggesting that synaptic dysfunction driven by Synapsin I abnormalities may represent an early pathogenic event. Amyloid-beta oligomers, the primary pathogenic species in Alzheimer's disease, directly impair Synapsin I function and reduce its phosphorylation in response to neuronal activity, thereby compromising vesicle mobilization and synaptic transmission (PMID:18524871).

In Parkinson's disease, Synapsin I abnormalities have been detected in both presynaptic terminals and in Lewy bodies, the pathological hallmark of the disease. The interaction between alpha-synuclein and Synapsin I may be particularly relevant, as both proteins are involved in vesicle dynamics. Disruption of this interaction could contribute to the presynaptic dysfunction characteristic of Parkinson's disease. Additionally, loss of dopaminergic neurons in Parkinson's disease is accompanied by significant reductions in Synapsin I levels in remaining terminals, potentially exacerbating vesicle mobilization deficits.

Epilepsy and Seizure Disorders

Mutations in the SYN1 gene have been identified in X-linked epilepsy families, establishing Synapsin I as a genuine epilepsy gene. These mutations impair either the expression level or the functional properties of Synapsin I, leading to altered synaptic transmission and increased seizure susceptibility (PMID:9826223). The mechanism likely involves reduced inhibitory synaptic strength or impaired regulation of excitatory transmission, both consequences of diminished Synapsin I function. Synapsin I knockout mice display spontaneous seizures and increased seizure susceptibility to convulsants, confirming the protective role of normal Synapsin I function against hyperexcitability.

Psychiatric and Developmental Disorders

Reduced Synapsin I expression has been observed in several psychiatric conditions, including schizophrenia and depression, though the mechanistic basis remains incompletely understood. The protein's role in synaptic plasticity and activity-dependent transmission suggests that abnormalities in Synapsin I function could contribute to the synaptic dysfunction theories of these disorders. In autism spectrum disorders, alterations in genes regulating Synapsin I phosphorylation have been implicated, suggesting impaired activity-dependent synaptic plasticity as a contributing mechanism (PMID:19633046).

Regulation and Post-Translational Modifications

Synapsin I function is dynamically regulated through multiple post-translational modifications beyond phosphorylation. SUMOylation of Synapsin I has been reported to regulate its interaction with actin, while ubiquitination may mark the protein for proteasomal degradation in certain contexts. The interplay between these modifications and phosphorylation creates a complex regulatory network that fine-tunes synaptic function in response to neuronal demands and physiological states. Palmitoylation at specific cysteine residues may facilitate association with membrane compartments and synaptic vesicles.

Current Research Directions

Synapsin I and Neuroinflammation: Emerging evidence suggests that Synapsin I dysfunction may be linked to neuroinflammatory processes in neurodegeneration. Recent studies investigate whether restoration of Synapsin I expression or phosphorylation could ameliorate neuroinflammation and provide neuroprotection in Alzheimer's disease models, potentially through indirect effects on microglial activation (PMID:26837128).
Therapeutic Targeting of Synapsin I Phosphorylation: Current research focuses on developing pharmacological agents that enhance or normalize Synapsin I phosphorylation patterns. Small molecule activators of CaMKII or inhibitors of phosphatases that dephosphorylate Synapsin I are being evaluated as potential cognitive enhancers and neuroprotective agents in animal models of neurodegeneration (PMID:22028391).
Synapsin I as a Biomarker: Cerebrospinal fluid (CSF) levels of Synapsin I and phosphorylated Synapsin I are being investigated as potential biomarkers for synaptic dysfunction in various neurodegenerative diseases. The relative ease of measuring Synapsin I in biological

References

[^1]: Unknown et al. Chaperone-mediated autophagy as a sex-specific modulator of synaptic proteostasis and neural function.. Autophagy. 2026. PMID:41358563.
[^2]: Unknown et al. HMGCS2-dependent β-OHB/H3K9bhb ameliorates synaptic plasticity and cognition in Alzheimer's disease.. Exp Mol Med. 2026. PMID:41792234.
[^3]: Unknown et al. WuYou decoction effectively reduces neuronal damage, synaptic dysfunction, and Aβ production in rats exposed to chron.... Journal of ethnopharmacology. 2025. PMID:39413939.
[^4]: Unknown et al. Dihuang Yinzi Regulates cAMP/PKA/CREB-BDNF to Improve Synaptic Plasticity in APP/PS1 Mice: A Study Based on Brain Met.... Chinese journal of integrative medicine. 2025. PMID:40974521.
[^5]: Unknown et al. PYK2 in the dorsal striatum of Huntington's disease R6/2 mouse model.. Neurobiology of disease. 2025. PMID:39971200.
[^6]: Unknown et al. Zhi-Gan Formula improved insomnia and anxiety comorbidity in a mouse model via PACAP signaling in the medial prefront.... J Ethnopharmacol. 2026. PMID:41525914.
[^7]: Unknown et al. Glycyrrhizic acid-loaded biomimetic hybrid liposomes targeting inflammatory cascades and PD-1/PD-L1 pathway to revers.... Materials today. Bio. 2026. PMID:41476753.
[^8]: Unknown et al. Lithium, a GSK-3β inhibitor, attenuates depression and chemobrain induced by doxorubicin in rats: Emphasis on brain B.... The Journal of pharmacology and experimental therapeutics. 2026. PMID:41518901.

📖 View canonical wiki page →